Drug firm Laurus Labs today said it has received approval from the US health regulator for its Metformin hydrochloride tablets used for treatment of diabetes.
The company has received approval from United States Food and Drug Administration (USFDA) for Metformin hydrochloride tablets USP in the strengths of 500 mg, 850 mg and 1,000 mg, Laurus Labs said in a BSE filing.
The tablets are generic versions of Bristol-Myers Squibb Company's Glucophage tablets in the same strengths, it added.
The product and API will be commercialised from company's Unit 2 located at Atchutapuram, Visakhapatnam in Andhra Pradesh, Laurus Labs said.
Shares of Laurus Labs today closed at Rs 438.70 per scrip on BSE, down 0.44 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app